Study explores adverse effects of SARS-CoV-2-induced antibody responses

study explores adverse effects of sars cov 2 induced antibody responses

Sumary of Study explores adverse effects of SARS-CoV-2-induced antibody responses:

  • Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggers an immune response driven by the immunoglobulin G (IgG) family of antibodies in the infected individual.
  • This response against the SARS-CoV-2 receptor-binding domain (RBD) is driven primarily by IgG1 and IgG3 sub-classes.
  • While several studies have established the positive outcomes of this antibody-mediated viral neutralization, its potential adverse effects are yet unknown.
  • Study: SARS-CoV-2 Antibodies Mediate Complement and Cellular Driven Inflammation.
  • Image Credit: Juan Gaertner / Shutterstock The study included a total of 180 people who recovered from coronavirus disease 2019 (COVID-19), as confirmed by their negative reverse transcription-polymerase chain reaction (RT-PCR) test.
  • The RT-PCR positive participants comprised males and females in the age group 18–86, with the course of disease ranging from mild (few symptoms) to severe (needed hospitalization).
  • Healthy blood donors were used as negative controls to collect a total of 60 EDTA plasma samples (from before 2020) having no SARS-CoV-2 antibodies.
  • Assessing levels of IgG sub-classes and complement molecules During natural infection, IgG1 and IgG3 sub-classes effectively activate the classical complement pathway to eliminate the pathogen (here SARS-CoV-2) employing methods such as microbial lysis by the terminal complement complex (TCC).

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close